In Phase A, participants will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled for the identified monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In https://daveyo777alv9.bloggosite.com/profile